Literature DB >> 8349811

Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism.

T A Buchanan1, H Thawani, W Kades, J G Modrall, F A Weaver, C Laurel, R Poppiti, A Xiang, W Hsueh.   

Abstract

To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (approximately 115 microU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (approximately 5,000 microU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (approximately 13 microU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349811      PMCID: PMC294906          DOI: 10.1172/JCI116642

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

2.  Effects on renal hemodynamics of intra-arterial infusions of angiotensins I and II.

Authors:  L Rosivall; L G Navar
Journal:  Am J Physiol       Date:  1983-08

3.  Control of renal function by intrarenal angiotensin II.

Authors:  N R Levens; A E Freedlender; M J Peach; R M Carey
Journal:  Endocrinology       Date:  1983-01       Impact factor: 4.736

4.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

5.  Quantitative evidence of peripheral conversion of angiotensin within the human leg: effects of local angiotensin-I administration and angiotensin-converting enzyme inhibition on regional blood flow and angiotensin-II balance across the leg.

Authors:  S Gasic; G Heinz; C Kleinbloesem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

6.  Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines.

Authors:  C Liang; J U Doherty; R Faillace; K Maekawa; S Arnold; H Gavras; W B Hood
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

7.  Body composition and glucose metabolism in hypertensive middle-aged males.

Authors:  G Berglund; B Larsson; O Andersson; O Larsson; K Svärdsudd; P Björntorp; L Wilhelmsen
Journal:  Acta Med Scand       Date:  1976

8.  In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus.

Authors:  A Kashiwagi; M A Verso; J Andrews; B Vasquez; G Reaven; J E Foley
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

9.  Mechanism of the postreceptor defect in insulin action in human obesity. Decrease in glucose transport system activity.

Authors:  T P Ciaraldi; O G Kolterman; J M Olefsky
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects.

Authors:  O G Kolterman; J Insel; M Saekow; J M Olefsky
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

View more
  25 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  Direct Activation of Angiotensin II Type 2 Receptors Enhances Muscle Microvascular Perfusion, Oxygenation, and Insulin Delivery in Male Rats.

Authors:  Fei Yan; Zhaoshun Yuan; Nasui Wang; Robert M Carey; Kevin W Aylor; Li Chen; Xinmin Zhou; Zhenqi Liu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

3.  Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle.

Authors:  Dino Premilovac; Emily Attrill; Stephen Rattigan; Stephen M Richards; Jeonga Kim; Michelle A Keske
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

Review 4.  Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.

Authors:  Eugene J Barrett; Hong Wang; Charles T Upchurch; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-24       Impact factor: 4.310

5.  Cross-talk between the insulin and angiotensin signaling systems.

Authors:  L A Velloso; F Folli; X J Sun; M F White; M J Saad; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity.

Authors:  H Laine; H Yki-Jarvinen; O Kirvela; T Tolvanen; M Raitakari; O Solin; M Haaparanta; J Knuuti; P Nuutila
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 7.  Angiotensin and insulin resistance: conspiracy theory.

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

Authors:  T A Buchanan; W P Meehan; Y Y Jeng; D Yang; T M Chan; J L Nadler; S Scott; R K Rude; W A Hsueh
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 9.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

10.  Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.

Authors:  H O Steinberg; G Brechtel; A Johnson; N Fineberg; A D Baron
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.